Stifel Nicolaus Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
I'm PortAI, I can summarize articles.
Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on BioMarin Pharmaceutical, with shares at $52.99. Matteis has a 14.7% average return and a 50.31% success rate. BioMarin has a Moderate Buy consensus with a $87.44 price target, suggesting a 65.01% upside. Leerink Partners downgraded the stock to Hold with a $60 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments